A 24-Week Treatment Strategy With Pegylated Interferon/Ribavirin in HIV/Hepatitis C Virus Genotype 3-Coinfected Patients Who Achieved a Rapid Virologic Response Results in a High Sustained Virologic Response Rate | Zendy

Antonio RiveroJuárez | Zendy; Luís F. LópezCortés | Zendy; Ángela Camacho | Zendy; J. A. Mira | Zendy; Francisco Téllez | Zendy; Manuel Márquez | Zendy; Dolores Merino | Zendy; Juan A. Pineda | Zendy; A. Rivero | Zendy

Open Access

A 24-Week Treatment Strategy With Pegylated Interferon/Ribavirin in HIV/Hepatitis C Virus Genotype 3-Coinfected Patients Who Achieved a Rapid Virologic Response Results in a High Sustained Virologic Response Rate

Author(s) -

Antonio RiveroJuárez,

Luís F. LópezCortés,

Ángela Camacho,

J. A. Mira,

Francisco Téllez,

Manuel Márquez,

Dolores Merino,

Juan A. Pineda,

A. Rivero

Publication year - 2013

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cit653

Subject(s) - ribavirin , medicine , pegylated interferon , hepatitis c virus , hepatitis c , population , virology , immunology , interferon , virus , gastroenterology , environmental health

We designed a study to evaluate the efficacy of a 24-week treatment strategy in HIV/hepatitis C virus (HCV) genotype 3-coinfected patients achieving rapid virologic response for a first HCV treatment with pegylated interferon plus ribavirin (peg-IFN/RBV). Our results suggest that a shorter course of peg-IFN/RBV therapy may be sufficient in this population.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research